UK MARKET TALK ROUNDUP: SHARES GAINING
21st Jul 2010 12:29
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1129 GMT [Dow Jones] Top line progression in GlaxoSmithKline's (GSK.LN) 1H results is pleasing, as is the significant cash
Read moreGlaxo's Second Quarter Results Hit By Legal Charge, Generics
21st Jul 2010 12:23
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK, GSK.LN) Wednesday missed earnings forecasts for the second quarter as continued strong sales of new products and its pandemic flu vaccine and further expansion in emerging markets was offset by generic compe
Read moreMARKET TALK: GlaxoSmithKline Shrs Nudge Tad Higher On 1H Data
21st Jul 2010 12:14
1114 GMT [Dow Jones] GlaxoSmithKline (GSK.LN) +0.4% at 1178.0p, nudging just a tad higher following its half-year report. A trader says there are no major surprises in the release. Previous 2010 cost guidance - cost of sales, selling, general and administrative expenses and R&D - is confirmed in th
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
21st Jul 2010 12:14
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1114 GMT [Dow Jones] GlaxoSmithKline (GSK.LN) +0.4% at 1178.0p, nudging just a tad higher following its half-year report. A
Read moreGlaxoSmithKline lifts sales but takes legal hit
21st Jul 2010 12:12
Drugmaker GlaxoSmithKline posted a rise in turnover in the second quarter, benefiting from bird 'flu vaccine sales and growth in emerging markets, but sustained a loss due to a charge for settling legal cases. Sales in the three months to June 30 were up to £7.025bn from £6.747bn over the same per
Read moreGenmab: Arzerra 2Q Net Sales DKK73M
21st Jul 2010 12:10
DOW JONES NEWSWIRES Genmab Wednesday said net sales of Arzerra for the second quarter of 2010 were approximately DKK73 million, with an expected royalty payment to Genmab of approximately DKK15 million. MAIN FACTS: -2Q net sales in the U.S. approximately DKK64 million. -2Q rest of th
Read moreLondon midday: Glaxo sales in line
21st Jul 2010 12:05
Equities ended the morning session in consolidation mode, holding on to the gains racked up in the first two hours of trading, when traders were enthused by the Reckitt Benckiser bid for SSL and forecast busting results overnight from Apple. Reckitt will pay SSL shareholders 1,163p per share with a
Read moreBEFORE THE BELL: US Stock Futures Up Before Bernanke Testimony
21st Jul 2010 11:01
By Polya Lesova U.S. stock futures rose on Wednesday, buoyed by Apple's stronger-than-expected results, as investors braced for testimony by Federal Reserve Chairman Ben Bernanke and another barrage of earnings reports. Futures on the Dow Jones Industrial Average rose 31 points to 10210. Th
Read moreShionogi, GlaxoSmithKline To Start Phase-3 Study For HIV Drug
21st Jul 2010 10:47
TOKYO (Dow Jones)--Shionogi & Co. (4507.TO) said Wednesday it and GlaxoSmithKline PLC (GSK) will start a phase-3 clinical study on their HIV infection treatment S/GSK1349572 following favorable results from second stage phase-2 trials. S/GSK1349572 is for HIV-infected patients who have never bee
Read morePRESS RELEASE: Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Program for Investigational Once-Daily HIV Integrase Inhibitor
21st Jul 2010 09:29
LONDON, July 21 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III cli
Read moreShionogi-ViiV Healthcare To Start Phase III Trial For HIV Drug
21st Jul 2010 09:19
LONDON (Dow Jones)--Shionogi-ViiV Healthcare LLC Wednesday said it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572, or 572, into Phase III clinical trials. MAIN FACTS: -This decision is based on promising results from two Phase IIb trials, SPRI
Read moreWednesday preview: Glaxo, Mitchells & Butlers, MPC
20th Jul 2010 17:42
In GlaxoSmithKline's second quarter results on Wednesday, Charles Stanley is looking for revenues of £6.99bn and £2bn profit. 'Expect these results to show continued growth in emerging market activities and a continued positive contribution over the quarter from H1N1 pandemic 'flu preparations est
Read moreGlaxoSmithKline Says Settles Certain Paxil Drug Lawsuits
20th Jul 2010 16:22
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK, GSK.LN) Tuesday said it has settled certain lawsuits alleging its Paxil antidepressant caused birth defects in some users but didn't give financial details. The U.K.'s biggest drug company said in an ema
Read moreGlaxoSmithKline Agrees To $1 Bln Paxil Settlement - Bloomberg
20th Jul 2010 15:50
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK) has agreed to pay more than $1 billion to resolve more than 800 cases alleging its Paxil antidepressant caused birth defects, Bloomberg reports Tuesday citing "people familiar with the settlements." The agreements leave more than 100 cases still pend
Read moreCORRECT:(7/19)EARNINGS PREVIEW: Glaxo 2Q Pre-Revamp Net Pft Seen -11%
20th Jul 2010 12:09
("EARNINGS PREVIEW: Glaxo 2Q Pre-Restructuring Net Pft Seen -11%" published at 1505 GMT July 19 misstated the release date in the second line. The correct version follows:) GlaxoSmithKline (GSK): 2Q Earnings Due: July 21 at 1100 GMT DJ Survey of 13 Analysts Average 2Q 2010 Net Profit Before Major R
Read more